Kyverna Therapeutics, Inc. KYTX Other Accrued Expenses And Current Liabilities
Other Accrued Expenses And Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept kytx:OtherAccruedExpensesAndCurrentLiabilities.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s other accrued expenses and current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s other accrued expenses and current liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported other accrued expenses and current liabilities of $9.22M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s other accrued expenses and current liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s other accrued expenses and current liabilities decreased by 22.5% year-over-year, from $11.91M to $9.22M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s other accrued expenses and current liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s other accrued expenses and current liabilities has grown at a 95.7% compound annual growth rate (CAGR), from $3.52M to $13.47M.
- What does other accrued expenses and current liabilities mean?
- This captures miscellaneous short-term obligations that do not fall under specific line items like accounts payable or accrued compensation. It typically includes routine operational costs, professional fees, or service-related expenses that have been incurred but not yet invoiced or paid. Tracking this balance provides insight into the company's general operational overhead and short-term working capital requirements.